<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Is Creatine Safe? What 500+ Studies Over 30 Years Tell Us</title>
  <meta name="description" content="Comprehensive safety review of creatine monohydrate based on over 500 peer-reviewed studies spanning three decades. Evidence from clinical trials,...">
  <meta name="robots" content="index, follow">
  <link rel="canonical" href="https://creatinepedia.com/safety/is-creatine-safe">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://creatinepedia.com/safety/is-creatine-safe">
  <meta property="og:title" content="Is Creatine Safe? What 500+ Studies Over 30 Years Tell Us">
  <meta property="og:description" content="Comprehensive safety review of creatine monohydrate based on over 500 peer-reviewed studies spanning three decades. Evidence from clinical trials,...">
  <meta property="og:site_name" content="Creatine Research">
  <meta name="twitter:card" content="summary_large_image">
  <meta name="twitter:title" content="Is Creatine Safe? What 500+ Studies Over 30 Years Tell Us">
  <meta name="twitter:description" content="Comprehensive safety review of creatine monohydrate based on over 500 peer-reviewed studies spanning three decades. Evidence from clinical trials,...">
  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect fill='%230f172a' width='100' height='100' rx='12'/><text x='50' y='68' font-family='monospace' font-size='40' fill='%230284c7' text-anchor='middle'>Cr</text></svg>">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=DM+Sans:wght@400;500;600;700&family=Instrument+Serif:ital@0;1&display=swap" rel="stylesheet">
  <script src="https://cdn.tailwindcss.com"></script>
  <script>
    tailwind.config = {
      darkMode: 'class',
      theme: {
        extend: {
          fontFamily: {
            sans: ['DM Sans', 'system-ui', 'sans-serif'],
            serif: ['Instrument Serif', 'Georgia', 'serif'],
          },
          colors: {
            slate: { 925: '#0c0f14', 950: '#090b10' }
          }
        }
      }
    }
  </script>
  <style>
    ::selection { background: rgba(2, 132, 199, 0.3); }
    ::-webkit-scrollbar { width: 8px; }
    ::-webkit-scrollbar-track { background: var(--bg-secondary, #18181b); }
    ::-webkit-scrollbar-thumb { background: var(--border, #27272a); border-radius: 4px; }
    ::-webkit-scrollbar-thumb:hover { background: #3f3f46; }

    /* Article body — light mode */
    .article-body { max-width: 720px; margin: 0 auto; padding: 0 1rem; }
    .article-body h1 { font-family: 'Instrument Serif', Georgia, serif; font-size: 2.75rem; line-height: 1.15; margin-bottom: 1rem; color: #0f172a; }
    .article-body h2 { font-family: 'Instrument Serif', Georgia, serif; font-size: 1.875rem; margin: 2.5rem 0 1rem; color: #0f172a; }
    .article-body h3 { font-size: 1.25rem; font-weight: 600; margin: 2rem 0 0.75rem; color: #0f172a; }
    .article-body p { margin-bottom: 1.5rem; color: #475569; line-height: 1.8; }
    .article-body a { color: #0284c7; text-decoration: none; }
    .article-body a:hover { text-decoration: underline; }
    .article-body ul, .article-body ol { margin: 1.5rem 0; padding-left: 1.5rem; color: #475569; }
    .article-body li { margin-bottom: 0.75rem; line-height: 1.7; }
    .article-body strong { color: #1e293b; }
    .article-body blockquote { border-left: 3px solid #0284c7; padding-left: 1.5rem; margin: 2rem 0; font-style: italic; color: #334155; }
    .article-body .meta { color: #64748b; font-size: 0.9rem; margin-bottom: 2rem; }
    .article-body table { width: 100%; border-collapse: collapse; margin: 2rem 0; }
    .article-body th, .article-body td { text-align: left; padding: 0.75rem 1rem; border-bottom: 1px solid #e2e8f0; color: #475569; }
    .article-body th { color: #0f172a; font-weight: 600; border-bottom: 2px solid #cbd5e1; }
    .article-body .cta-box {
      background: linear-gradient(135deg, rgba(2, 132, 199, 0.08), rgba(13, 148, 136, 0.04));
      border: 1px solid rgba(2, 132, 199, 0.2);
      border-radius: 16px; padding: 2.5rem; margin: 3rem 0; text-align: center;
    }
    .article-body .cta-box h3 { margin-top: 0; font-family: 'Instrument Serif', Georgia, serif; font-size: 1.5rem; }
    .article-body .cta-box p { color: #64748b; margin-bottom: 1.5rem; }
    .article-body .cta-button {
      display: inline-block; background: #0284c7; color: #ffffff;
      padding: 1rem 2rem; border-radius: 8px; font-weight: 600;
      text-decoration: none; transition: background 0.2s;
    }
    .article-body .cta-button:hover { background: #0ea5e9; text-decoration: none; }
    .article-body .related-articles { margin-top: 3rem; padding-top: 2rem; border-top: 1px solid #e2e8f0; }
    .article-body .related-articles h3 { margin-bottom: 1rem; }
    .article-body .related-articles ul { list-style: none; padding: 0; }
    .article-body .related-articles li { margin-bottom: 0.5rem; }
    .article-body .faq-section { margin-top: 3rem; padding-top: 2rem; border-top: 1px solid #e2e8f0; }
    .article-body .faq-section > h2 { margin-top: 0; }
    .article-body .faq-item { margin-bottom: 2rem; }
    .article-body .faq-item h3 { color: #0f172a; margin-bottom: 0.5rem; }
    .article-body .faq-item p { margin-bottom: 0; }

    /* Article body — dark mode */
    .dark .article-body h1, .dark .article-body h2, .dark .article-body h3 { color: #fafaf9; }
    .dark .article-body p { color: #a1a1aa; }
    .dark .article-body ul, .dark .article-body ol { color: #a1a1aa; }
    .dark .article-body strong { color: #e4e4e7; }
    .dark .article-body a { color: #38bdf8; }
    .dark .article-body blockquote { color: #d4d4d8; }
    .dark .article-body .meta { color: #71717a; }
    .dark .article-body th, .dark .article-body td { border-bottom-color: #27272a; color: #a1a1aa; }
    .dark .article-body th { color: #fafaf9; border-bottom-color: #3f3f46; }
    .dark .article-body .cta-box { background: linear-gradient(135deg, rgba(2, 132, 199, 0.12), rgba(13, 148, 136, 0.06)); }
    .dark .article-body .cta-box p { color: #a1a1aa; }
    .dark .article-body .related-articles { border-top-color: #27272a; }
    .dark .article-body .faq-section { border-top-color: #27272a; }
    .dark .article-body .faq-item h3 { color: #fafaf9; }

    /* Newsletter section */
    #newsletter input::placeholder { color: #94a3b8; }
    .dark #newsletter input::placeholder { color: #52525b; }


    /* Mega menu */
    .mega-panel { transition: opacity 0.15s ease, visibility 0.15s ease; }
    .mega-panel.hidden { opacity: 0; visibility: hidden; display: none; }
    .mega-panel:not(.hidden) { opacity: 1; visibility: visible; display: block; }
    .mega-link {
      display: block; padding: 6px 0;
      font-size: 0.875rem; color: #475569;
      transition: color 0.15s;
    }
    .mega-link:hover { color: #0f172a; text-decoration: none; }
    .dark .mega-link { color: #a1a1aa; }
    .dark .mega-link:hover { color: #fafaf9; }
    .mega-view-all {
      display: inline-block; margin-top: 12px;
      font-size: 0.8125rem; font-weight: 500;
      color: #0284c7; transition: color 0.15s;
    }
    .mega-view-all:hover { color: #0ea5e9; text-decoration: none; }
    .dark .mega-view-all { color: #38bdf8; }
    .dark .mega-view-all:hover { color: #7dd3fc; }

    /* Nav effects */
    .nav-link { position: relative; }
    .nav-link::after {
      content: ''; position: absolute; bottom: -2px; left: 0;
      width: 0; height: 1px; background: #0284c7; transition: width 0.3s ease;
    }
    .nav-link:hover::after { width: 100%; }
    .cta-glow { position: relative; }
    .cta-glow::before {
      content: ''; position: absolute; inset: -2px;
      background: linear-gradient(135deg, #0284c7, #0891b2);
      border-radius: inherit; opacity: 0; filter: blur(12px);
      transition: opacity 0.3s ease; z-index: -1;
    }
    .cta-glow:hover::before { opacity: 0.4; }

    /* Active trigger state */
    .mega-trigger[aria-expanded="true"] { color: #0f172a; }
    .dark .mega-trigger[aria-expanded="true"] { color: #fafaf9; }
    .mega-trigger[aria-expanded="true"] svg { transform: rotate(180deg); }


    @media (max-width: 768px) {
      .article-body h1 { font-size: 2rem; }
      .article-body h2 { font-size: 1.5rem; }
    }
  </style>
  <script type="application/ld+json">
  {
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What is the scope of the evidence base?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Understanding creatine safety requires appreciating the sheer volume of research. Kreider et al. published a landmark review in 2017 in the Journal of the International Society of Sports Nutrition, analyzing data accumulated over two decades. Their review encompassed studies in athletes, sedentary individuals, children, elderly populations, and clinical patients. The consistent finding across these diverse groups was that creatine monohydrate at recommended doses (3-5 g/day for maintenance, or 20 g/day during a 5-7 day loading phase) produced no clinically significant adverse effects."
      }
    },
    {
      "@type": "Question",
      "name": "What \"Safe\" Means in Research Terms?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "When researchers evaluate supplement safety, they look at specific biomarkers. For creatine, the key indicators include renal function markers (blood urea nitrogen, serum creatinine, glomerular filtration rate), hepatic enzymes (ALT, AST), lipid profiles, blood glucose, electrolyte balance, and hematological parameters. Studies measuring these markers before and after creatine supplementation periods ranging from weeks to years have consistently shown values remaining within normal clinical ranges."
      }
    },
    {
      "@type": "Question",
      "name": "What is the populations studied?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The breadth of populations studied strengthens the safety case considerably. Research has examined creatine supplementation in:"
      }
    },
    {
      "@type": "Question",
      "name": "What are the common concerns addressed?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Several safety concerns about creatine have achieved widespread cultural traction despite lacking clinical support. Each is addressed briefly here and in dedicated articles throughout this section."
      }
    },
    {
      "@type": "Question",
      "name": "What is the long-term data?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Short-term safety is well-established, but long-term data strengthens the case further. Schilling et al. (2001) examined athletes who had used creatine for up to four years. Comprehensive metabolic panels showed no differences between long-term creatine users and non-users. Kreider et al. (2003) published similar findings from multi-year follow-ups."
      }
    }
  ]
}
  </script>
</head>
<body class="bg-slate-50 dark:bg-slate-950 font-sans antialiased">

  <nav class="fixed top-0 left-0 right-0 z-50 border-b border-slate-200 dark:border-zinc-800/60 bg-white/90 dark:bg-slate-950/90 backdrop-blur-md">
    <div class="max-w-7xl mx-auto">
      <div class="flex items-center justify-between h-16 px-6">
        <!-- Logo -->
        <a href="/" class="flex items-center gap-3 group">
          <div class="w-8 h-8 rounded-md bg-slate-100 dark:bg-zinc-800 border border-slate-200 dark:border-zinc-700 flex items-center justify-center group-hover:border-sky-500/50 transition-colors">
            <svg class="w-4 h-4 text-sky-600 dark:text-sky-400" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"></path></svg>
          </div>
          <span class="text-slate-500 dark:text-zinc-400 text-sm tracking-tight">
            <span class="text-slate-800 dark:text-zinc-200 font-medium">Creatine</span><span class="text-sky-600 dark:text-sky-400">Research</span>
          </span>
        </a>

        <!-- Desktop Nav -->
        <div class="hidden lg:flex items-center gap-1">

          <!-- Science dropdown -->
          <div class="relative" data-mega="science">
            <button class="mega-trigger nav-link px-4 py-2 text-sm text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-zinc-200 transition-colors flex items-center gap-1">
              Research
              <svg class="w-3 h-3 opacity-50 transition-transform" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
            </button>
          </div>

          <!-- Applications dropdown -->
          <div class="relative" data-mega="applications">
            <button class="mega-trigger nav-link px-4 py-2 text-sm text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-zinc-200 transition-colors flex items-center gap-1">
              Applications
              <svg class="w-3 h-3 opacity-50 transition-transform" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
            </button>
          </div>

          <!-- All Articles link -->
          <a href="/articles" class="nav-link px-4 py-2 text-sm text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-zinc-200 transition-colors">All Articles</a>

          <div class="w-px h-4 bg-slate-300 dark:bg-zinc-800 mx-2"></div>

          <!-- CTA -->
          <a href="#newsletter" class="px-5 py-2 text-sm font-semibold bg-sky-600 hover:bg-sky-500 text-white rounded-md transition-colors cta-glow">Research Updates</a>
        </div>

        <!-- Mobile menu button -->
        <button id="mobile-menu-btn" class="lg:hidden p-2 text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-zinc-200">
          <svg id="menu-icon" class="w-5 h-5" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
          <svg id="close-icon" class="w-5 h-5 hidden" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M6 18L18 6M6 6l12 12"></path></svg>
        </button>
      </div>

      <!-- ═══ MEGA PANEL: Research ═══ -->
      <div id="mega-science" class="mega-panel hidden border-t border-slate-200 dark:border-zinc-800/60 bg-white dark:bg-slate-950">
        <div class="max-w-7xl mx-auto px-6 py-8">
          <div class="grid grid-cols-3 gap-8">
            <!-- Column 1: Science -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-sky-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">Science & Mechanisms</span>
              </div>
              <div class="space-y-1">
                <a href="/science/what-is-creatine-monohydrate" class="mega-link">What Is Creatine Monohydrate?</a>
                <a href="/science/how-creatine-works-in-the-body" class="mega-link">How Creatine Works</a>
                <a href="/science/creatine-atp-resynthesis" class="mega-link">ATP Resynthesis</a>
                <a href="/science/creatine-and-muscle-growth" class="mega-link">Muscle Growth Research</a>
                <a href="/science/creatine-and-brain-function" class="mega-link">Brain Function</a>
                <a href="/science/creatine-and-aging" class="mega-link">Aging & Sarcopenia</a>
              </div>
              <a href="/science" class="mega-view-all">All 20 articles &rarr;</a>
            </div>

            <!-- Column 2: Dosing & Safety -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-teal-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">Dosing & Safety</span>
              </div>
              <div class="space-y-1">
                <a href="/dosing/creatine-loading-protocol" class="mega-link">Loading Protocol</a>
                <a href="/dosing/creatine-maintenance-dose" class="mega-link">Maintenance Dosing</a>
                <a href="/dosing/creatine-timing-before-or-after-workout" class="mega-link">Timing: Before or After?</a>
                <a href="/safety/is-creatine-safe" class="mega-link">Is Creatine Safe?</a>
                <a href="/safety/creatine-and-kidneys" class="mega-link">Kidney Health</a>
                <a href="/safety/creatine-and-hair-loss" class="mega-link">Hair Loss Myth</a>
              </div>
              <a href="/dosing" class="mega-view-all">Dosing (15) &rarr;</a>
              <span class="mx-2 text-slate-300 dark:text-zinc-700">|</span>
              <a href="/safety" class="mega-view-all">Safety (15) &rarr;</a>
            </div>

            <!-- Column 3: CTA Card -->
            <div class="bg-gradient-to-br from-sky-500/10 to-teal-500/5 dark:from-sky-500/15 dark:to-teal-500/5 border border-sky-500/20 rounded-xl p-6 flex flex-col justify-between">
              <div>
                <h3 class="text-lg font-semibold text-slate-900 dark:text-zinc-100 mb-2">Evidence-Based Research</h3>
                <p class="text-sm text-slate-600 dark:text-zinc-400 mb-4">Every article cites peer-reviewed studies. No marketing hype. Just what the science shows.</p>
              </div>
              <a href="/science/creatine-mechanisms-summary" class="inline-flex items-center justify-center px-6 py-3 bg-sky-600 hover:bg-sky-500 text-white font-semibold rounded-lg text-sm transition-colors cta-glow">
                Complete Research Guide
              </a>
            </div>
          </div>
        </div>
      </div>

      <!-- ═══ MEGA PANEL: Applications ═══ -->
      <div id="mega-applications" class="mega-panel hidden border-t border-slate-200 dark:border-zinc-800/60 bg-white dark:bg-slate-950">
        <div class="max-w-7xl mx-auto px-6 py-8">
          <div class="grid grid-cols-4 gap-8">
            <!-- Column 1: By Sport -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-amber-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 10V3L4 14h7v7l9-11h-7z"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">By Sport</span>
              </div>
              <div class="space-y-1">
                <a href="/sports/creatine-for-powerlifting" class="mega-link">Powerlifting</a>
                <a href="/sports/creatine-for-bodybuilding" class="mega-link">Bodybuilding</a>
                <a href="/sports/creatine-for-crossfit" class="mega-link">CrossFit</a>
                <a href="/sports/creatine-for-mma" class="mega-link">MMA & Combat Sports</a>
                <a href="/sports/creatine-for-soccer" class="mega-link">Soccer</a>
                <a href="/sports/creatine-for-swimming" class="mega-link">Swimming</a>
              </div>
              <a href="/sports" class="mega-view-all">All 20 sports &rarr;</a>
            </div>

            <!-- Column 2: Comparisons -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-violet-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M8 7h12m0 0l-4-4m4 4l-4 4m0 6H4m0 0l4 4m-4-4l4-4"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">vs Other Supplements</span>
              </div>
              <div class="space-y-1">
                <a href="/comparisons/creatine-vs-protein-powder" class="mega-link">vs Protein Powder</a>
                <a href="/comparisons/creatine-vs-bcaa" class="mega-link">vs BCAAs</a>
                <a href="/comparisons/creatine-vs-beta-alanine" class="mega-link">vs Beta-Alanine</a>
                <a href="/comparisons/creatine-vs-pre-workout" class="mega-link">vs Pre-Workout</a>
                <a href="/comparisons/creatine-vs-ashwagandha" class="mega-link">vs Ashwagandha</a>
              </div>
              <a href="/comparisons" class="mega-view-all">All 15 comparisons &rarr;</a>
            </div>

            <!-- Column 3: Product Quality -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-emerald-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m5.618-4.016A11.955 11.955 0 0112 2.944a11.955 11.955 0 01-8.618 3.04A12.02 12.02 0 003 9c0 5.591 3.824 10.29 9 11.622 5.176-1.332 9-6.03 9-11.622 0-1.042-.133-2.052-.382-3.016z"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">Product Quality</span>
              </div>
              <div class="space-y-1">
                <a href="/quality/creatine-monohydrate-vs-hcl" class="mega-link">Monohydrate vs HCl</a>
                <a href="/quality/creatine-forms-comparison" class="mega-link">All Forms Compared</a>
                <a href="/quality/third-party-testing-creatine" class="mega-link">Third-Party Testing</a>
                <a href="/quality/creapure-vs-generic-creatine" class="mega-link">Creapure vs Generic</a>
                <a href="/quality/creatine-buying-guide" class="mega-link">Buying Guide</a>
              </div>
              <a href="/quality" class="mega-view-all">All 15 guides &rarr;</a>
            </div>

            <!-- Column 4: Quick Links -->
            <div>
              <div class="flex items-center gap-2 mb-4">
                <svg class="w-4 h-4 text-sky-500" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 7h8m0 0v8m0-8l-8 8-4-4-6 6"></path></svg>
                <span class="text-xs font-semibold tracking-wider text-slate-500 dark:text-zinc-500 uppercase">Quick Links</span>
              </div>
              <div class="space-y-1">
                <a href="/science/creatine-mechanisms-summary" class="mega-link">Complete Science Guide</a>
                <a href="/dosing/creatine-dosing-protocols-summary" class="mega-link">Complete Dosing Guide</a>
                <a href="/safety/creatine-safety-complete-guide" class="mega-link">Complete Safety Guide</a>
                <a href="/sports/creatine-for-sport-summary" class="mega-link">Every Sport Guide</a>
                <a href="/quality/creatine-buying-guide" class="mega-link">Buying Guide</a>
              </div>
              <a href="/articles" class="mega-view-all">All 100 articles &rarr;</a>
            </div>
          </div>
        </div>
      </div>

      <!-- ═══ Mobile Menu ═══ -->
      <div id="mobile-menu" class="hidden lg:hidden border-t border-slate-200 dark:border-zinc-800 bg-white dark:bg-slate-950 max-h-[80vh] overflow-y-auto">
        <div class="px-6 py-4 space-y-1">
          <!-- Research -->
          <button class="mobile-section-toggle w-full flex items-center justify-between py-3 text-slate-800 dark:text-zinc-200 font-medium">
            Research
            <svg class="w-4 h-4 text-slate-400 dark:text-zinc-600 transition-transform" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
          </button>
          <div class="mobile-section hidden pl-4 pb-3 space-y-1">
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-1 pb-1">Science</p>
            <a href="/science/what-is-creatine-monohydrate" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">What Is Creatine?</a>
            <a href="/science/how-creatine-works-in-the-body" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">How Creatine Works</a>
            <a href="/science" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 20 articles &rarr;</a>
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-3 pb-1">Dosing</p>
            <a href="/dosing/creatine-loading-protocol" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Loading Protocol</a>
            <a href="/dosing/creatine-maintenance-dose" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Maintenance Dose</a>
            <a href="/dosing" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 15 articles &rarr;</a>
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-3 pb-1">Safety</p>
            <a href="/safety/is-creatine-safe" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Is Creatine Safe?</a>
            <a href="/safety/creatine-and-kidneys" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Kidney Health</a>
            <a href="/safety" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 15 articles &rarr;</a>
          </div>

          <!-- Applications -->
          <button class="mobile-section-toggle w-full flex items-center justify-between py-3 text-slate-800 dark:text-zinc-200 font-medium">
            Applications
            <svg class="w-4 h-4 text-slate-400 dark:text-zinc-600 transition-transform" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
          </button>
          <div class="mobile-section hidden pl-4 pb-3 space-y-1">
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-1 pb-1">Sports</p>
            <a href="/sports/creatine-for-powerlifting" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Powerlifting</a>
            <a href="/sports/creatine-for-bodybuilding" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">Bodybuilding</a>
            <a href="/sports" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 20 sports &rarr;</a>
            <p class="text-xs text-slate-400 dark:text-zinc-600 uppercase tracking-wider pt-3 pb-1">Comparisons</p>
            <a href="/comparisons/creatine-vs-protein-powder" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">vs Protein Powder</a>
            <a href="/comparisons/creatine-vs-bcaa" class="block py-1.5 text-sm text-slate-600 dark:text-zinc-400 hover:text-slate-900 dark:hover:text-white">vs BCAAs</a>
            <a href="/comparisons" class="block py-1.5 text-sm text-sky-600 dark:text-sky-400 font-medium">All 15 comparisons &rarr;</a>
          </div>

          <!-- Direct links -->
          <a href="/articles" class="block py-3 text-slate-800 dark:text-zinc-200 font-medium">All Articles</a>

          <!-- CTA -->
          <a href="#newsletter" class="block mt-4 py-3 bg-sky-600 text-white text-center font-semibold rounded-lg">Get Research Updates</a>
        </div>
      </div>
    </div>
  </nav>

  <main class="pt-24 pb-16">
    <div class="max-w-3xl mx-auto px-4 sm:px-6 mb-6">
      <div class="flex items-center gap-2 text-sm">
        <a href="/" class="text-slate-400 dark:text-zinc-600 hover:text-slate-600 dark:hover:text-zinc-400 transition-colors">Home</a>
        <span class="text-slate-300 dark:text-zinc-700">/</span>
        <a href="/articles" class="text-slate-400 dark:text-zinc-600 hover:text-slate-600 dark:hover:text-zinc-400 transition-colors">Articles</a>
        <span class="text-slate-300 dark:text-zinc-700">/</span>
        <a href="/safety" class="text-slate-400 dark:text-zinc-600 hover:text-slate-600 dark:hover:text-zinc-400 transition-colors">Safety & Concerns</a>
      </div>
    </div>
    <div class="article-body">
      <article>
    <h1>Is Creatine Safe? What 500+ Studies Over 30 Years Tell Us</h1>

    <p>Creatine monohydrate is the single most studied sports supplement in history. Since the early 1990s, when creatine entered mainstream athletic use following the Barcelona Olympics, researchers have produced over 500 peer-reviewed papers examining its effects on the human body. The question of safety has been addressed repeatedly, from multiple angles, across diverse populations. The accumulated evidence is unambiguous.</p>

    <p>The International Society of Sports Nutrition (ISSN), the American College of Sports Medicine, and the European Food Safety Authority have all reviewed the creatine literature. Their consensus: creatine monohydrate, when used at established doses, is safe for healthy individuals. This article walks through the evidence supporting that position and addresses the caveats that responsible science demands.</p>

    <h2>The Scope of the Evidence Base</h2>

    <p>Understanding creatine safety requires appreciating the sheer volume of research. Kreider et al. published a landmark review in 2017 in the <em>Journal of the International Society of Sports Nutrition</em>, analyzing data accumulated over two decades. Their review encompassed studies in athletes, sedentary individuals, children, elderly populations, and clinical patients. The consistent finding across these diverse groups was that creatine monohydrate at recommended doses (3-5 g/day for maintenance, or 20 g/day during a 5-7 day loading phase) produced no clinically significant adverse effects.</p>

    <p>Persky and Brazeau (2001), writing in <em>Pharmacological Reviews</em>, conducted one of the earliest comprehensive safety analyses. They reviewed creatine's pharmacokinetics, metabolic pathways, and reported side effects. Their conclusion noted that the compound's safety profile was well-characterized and that reported adverse events were overwhelmingly anecdotal rather than clinically documented.</p>

    <p>The ISSN Position Stand on creatine supplementation, most recently updated with contributions from Kreider and colleagues, states explicitly that creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes for increasing high-intensity exercise capacity and lean body mass during training. The position stand also notes that there is no scientific evidence that short- or long-term use of creatine monohydrate has any detrimental effects on otherwise healthy individuals when used at established guidelines.</p>

    <h2>What "Safe" Means in Research Terms</h2>

    <p>When researchers evaluate supplement safety, they look at specific biomarkers. For creatine, the key indicators include renal function markers (blood urea nitrogen, serum creatinine, glomerular filtration rate), hepatic enzymes (ALT, AST), lipid profiles, blood glucose, electrolyte balance, and hematological parameters. Studies measuring these markers before and after creatine supplementation periods ranging from weeks to years have consistently shown values remaining within normal clinical ranges.</p>

    <p>Poortmans and Francaux (1999), in a study published in <em>Medicine &amp; Science in Sports &amp; Exercise</em>, specifically examined renal function in creatine users. They found no evidence of impaired renal function as measured by glomerular filtration rate, albumin excretion rate, or serum creatinine (when properly interpreted). This study became foundational in addressing the persistent myth that creatine damages kidneys.</p>

    <p>A critical distinction researchers make is between an elevated serum creatinine reading and actual kidney dysfunction. Creatine is naturally converted to creatinine as a metabolic byproduct. Supplementation increases this conversion, which can elevate serum creatinine without any corresponding decline in kidney function. Clinicians unfamiliar with this mechanism sometimes misinterpret routine blood work in creatine users, a problem explored in detail in the article on <a href="/safety/creatine-and-creatinine-levels">creatine and creatinine levels</a>.</p>

    <h2>Populations Studied</h2>

    <p>The breadth of populations studied strengthens the safety case considerably. Research has examined creatine supplementation in:</p>

    <p><strong>Trained athletes.</strong> Hundreds of studies have used competitive and recreational athletes as subjects. These individuals often take creatine for months or years. No pattern of adverse effects has emerged in any sport or training modality studied.</p>

    <p><strong>Older adults.</strong> With growing interest in creatine's potential to combat sarcopenia (age-related muscle loss) and cognitive decline, multiple studies have supplemented adults aged 55-80+ with creatine. These populations are particularly sensitive to kidney and cardiovascular stressors, yet no adverse effects have been reported.</p>

    <p><strong>Children and adolescents.</strong> While research in younger populations is more limited, existing studies in pediatric clinical settings (particularly for traumatic brain injury and muscular dystrophies) have not identified safety concerns. The ISSN notes that creatine may be a safer alternative to potentially dangerous anabolic substances that adolescents might otherwise seek.</p>

    <p><strong>Clinical populations.</strong> Creatine has been studied in patients with Parkinson's disease, Huntington's disease, ALS, muscular dystrophies, type 2 diabetes, traumatic brain injury, and depression. Even in these medically complex populations, the safety profile has remained favorable.</p>

    <h2>Common Concerns Addressed</h2>

    <p>Several safety concerns about creatine have achieved widespread cultural traction despite lacking clinical support. Each is addressed briefly here and in dedicated articles throughout this section.</p>

    <p><strong>Kidney damage.</strong> The most persistent concern. As detailed in the <a href="/safety/creatine-and-kidneys">creatine and kidney health</a> article, no controlled study has demonstrated kidney damage in healthy individuals taking creatine at recommended doses. The concern appears to originate from a single case report and confusion between creatinine levels and kidney function.</p>

    <p><strong>Dehydration and cramping.</strong> Early speculation suggested that creatine's intracellular water retention might cause dehydration or muscle cramps during exercise. Controlled studies, including the work of Lopez et al. (2009) and Greenwood et al. (2003), found the opposite: creatine users experienced equal or fewer instances of cramping and dehydration compared to non-users.</p>

    <p><strong>Hair loss.</strong> A single study by van der Merwe et al. (2009) in South African rugby players found elevated DHT levels after a creatine loading protocol. No actual hair loss was measured or reported. No subsequent study has replicated this finding. The details are covered in the <a href="/safety/creatine-and-hair-loss">creatine and hair loss</a> article.</p>

    <p><strong>Liver damage.</strong> Hepatic function markers have been measured in numerous creatine trials. No evidence of liver damage or dysfunction has been found. See the <a href="/safety/creatine-and-liver">creatine and liver function</a> article for the clinical data.</p>

    <h2>Long-Term Data</h2>

    <p>Short-term safety is well-established, but long-term data strengthens the case further. Schilling et al. (2001) examined athletes who had used creatine for up to four years. Comprehensive metabolic panels showed no differences between long-term creatine users and non-users. Kreider et al. (2003) published similar findings from multi-year follow-ups.</p>

    <p>The fact that creatine has been commercially available since the mid-1990s provides an additional layer of pharmacovigilance data. Millions of people have used creatine over three decades. If significant health risks existed at recommended doses, they would have generated signal in adverse event reporting systems and epidemiological data by now. No such signal has appeared.</p>

    <h2>Dose Matters</h2>

    <p>Safety data applies to established dosing protocols. The standard maintenance dose is 3-5 grams per day. Loading protocols use 20 grams per day (divided into 4 doses of 5 grams) for 5-7 days before dropping to maintenance. These protocols are the ones validated for both efficacy and safety.</p>

    <p>Extremely high doses (beyond what studies have tested) fall outside the evidence base. This is true of any substance, including water. The safety literature does not support doses substantially above those used in controlled research, and there is no ergogenic reason to exceed them since muscle creatine stores have a saturation point.</p>

    <h2>Who Should Exercise Caution</h2>

    <p>While creatine is safe for the general healthy population, certain groups warrant additional consideration:</p>

    <p><strong>Pre-existing kidney disease.</strong> Individuals with compromised renal function should consult a nephrologist before supplementing. The safety data applies to healthy kidneys. While no study has shown creatine worsens existing kidney disease, insufficient research exists in this population to make definitive claims.</p>

    <p><strong>Pregnancy and breastfeeding.</strong> Research on creatine during pregnancy is emerging and shows theoretical promise (particularly for fetal neuroprotection), but the evidence is not yet sufficient to recommend supplementation during pregnancy without medical guidance. See the <a href="/safety/creatine-during-pregnancy">creatine during pregnancy</a> article.</p>

    <p><strong>Medication interactions.</strong> Individuals taking nephrotoxic drugs or medications metabolized through the kidneys should discuss creatine use with their physician. Theoretical interactions exist, though clinically significant interactions have not been documented. The <a href="/safety/creatine-drug-interactions">drug interactions</a> article covers this in detail.</p>

    <h2>The Bottom Line</h2>

    <p>Creatine monohydrate has been studied more extensively than any other sports supplement. Across 500+ peer-reviewed papers, in populations ranging from children to the elderly, from healthy athletes to clinical patients, the safety data is remarkably consistent. At recommended doses of 3-5 g/day, creatine monohydrate does not damage the kidneys, liver, or heart. It does not cause dehydration, cramping, or hair loss. It is not a steroid and does not function as one.</p>

    <p>The position statements from the ISSN, the accumulated clinical trial data, and three decades of widespread commercial use all point to the same conclusion: creatine monohydrate is safe for healthy individuals. The appropriate caveats involve pre-existing medical conditions and unstudied populations, which is standard for any supplement or dietary intervention.</p>

    <section>
      <h2>Bibliography</h2>
      <ol>
        <li>Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. <em>J Int Soc Sports Nutr</em>. 2017;14:18. doi:10.1186/s12970-017-0173-z</li>
        <li>Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. <em>Pharmacol Rev</em>. 2001;53(2):161-176. PMID: 11356982</li>
        <li>Poortmans JR, Francaux M. Long-term oral creatine supplementation does not impair renal function in healthy athletes. <em>Med Sci Sports Exerc</em>. 1999;31(8):1108-1110. doi:10.1097/00005768-199908000-00005</li>
        <li>Schilling BK, Stone MH, Utter A, et al. Creatine supplementation and health variables: a retrospective study. <em>Med Sci Sports Exerc</em>. 2001;33(2):183-188. doi:10.1097/00005768-200102000-00002</li>
        <li>Kreider RB, Melton C, Rasmussen CJ, et al. Long-term creatine supplementation does not significantly affect clinical markers of health in athletes. <em>Mol Cell Biochem</em>. 2003;244(1-2):95-104. doi:10.1023/A:1022469320296</li>
        <li>van der Merwe J, Brooks NE, Myburgh KH. Three weeks of creatine monohydrate supplementation affects dihydrotestosterone to testosterone ratio in college-aged rugby players. <em>Clin J Sport Med</em>. 2009;19(5):399-404. doi:10.1097/JSM.0b013e3181b8b52f</li>
        <li>Lopez RM, Casa DJ, McDermott BP, et al. Does creatine supplementation hinder exercise heat tolerance or hydration status? A systematic review with meta-analyses. <em>J Athl Train</em>. 2009;44(2):215-223. doi:10.4085/1062-6050-44.2.215</li>
        <li>Greenwood M, Kreider RB, Greenwood L, Byars A. Cramping and injury incidence in collegiate football players are reduced by creatine supplementation. <em>J Athl Train</em>. 2003;38(3):216-219. PMID: 14608430</li>
      </ol>
    </section>
      
      
      
      <section class="faq-section">
        <h2>Frequently Asked Questions</h2>
        
        <div class="faq-item">
          <h3>What is the scope of the evidence base?</h3>
          <p>Understanding creatine safety requires appreciating the sheer volume of research. Kreider et al. published a landmark review in 2017 in the Journal of the International Society of Sports Nutrition, analyzing data accumulated over two decades. Their review encompassed studies in athletes, sedentary individuals, children, elderly populations, and clinical patients. The consistent finding across these diverse groups was that creatine monohydrate at recommended doses (3-5 g/day for maintenance, or 20 g/day during a 5-7 day loading phase) produced no clinically significant adverse effects.</p>
        </div>
        <div class="faq-item">
          <h3>What "Safe" Means in Research Terms?</h3>
          <p>When researchers evaluate supplement safety, they look at specific biomarkers. For creatine, the key indicators include renal function markers (blood urea nitrogen, serum creatinine, glomerular filtration rate), hepatic enzymes (ALT, AST), lipid profiles, blood glucose, electrolyte balance, and hematological parameters. Studies measuring these markers before and after creatine supplementation periods ranging from weeks to years have consistently shown values remaining within normal clinical ranges.</p>
        </div>
        <div class="faq-item">
          <h3>What is the populations studied?</h3>
          <p>The breadth of populations studied strengthens the safety case considerably. Research has examined creatine supplementation in:</p>
        </div>
        <div class="faq-item">
          <h3>What are the common concerns addressed?</h3>
          <p>Several safety concerns about creatine have achieved widespread cultural traction despite lacking clinical support. Each is addressed briefly here and in dedicated articles throughout this section.</p>
        </div>
        <div class="faq-item">
          <h3>What is the long-term data?</h3>
          <p>Short-term safety is well-established, but long-term data strengthens the case further. Schilling et al. (2001) examined athletes who had used creatine for up to four years. Comprehensive metabolic panels showed no differences between long-term creatine users and non-users. Kreider et al. (2003) published similar findings from multi-year follow-ups.</p>
        </div>
      </section>
      </article>

      <!-- In-article CTA -->
      <div class="cta-box">
        <h3>Stay Current on Creatine Research</h3>
        <p>Get evidence-based updates when new studies are published. No hype, no marketing — just what the science shows.</p>
        <a href="#newsletter" class="cta-button">Get Research Updates</a>
      </div>

      <!-- Pillar page link -->
      <div class="related-articles">
        <h3>Read the Full Guide</h3>
        <p style="margin-bottom: 0.75rem;"><a href="/safety/creatine-safety-complete-guide">Complete Safety Guide: Safety & Concerns</a> — comprehensive overview with all cited sources.</p>
      </div>
    </div>

    <!-- Category nav -->
    <div class="max-w-3xl mx-auto px-4 sm:px-6 mt-12">
      <div class="flex items-center justify-between p-5 bg-slate-100 dark:bg-zinc-900/50 border border-slate-200 dark:border-zinc-800/60 rounded-xl">
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-1">Category</p>
          <a href="/safety" class="text-slate-800 dark:text-zinc-200 font-medium hover:text-sky-600 dark:hover:text-sky-400 transition-colors">Safety & Concerns</a>
        </div>
        <a href="/safety" class="text-sm text-sky-600 dark:text-sky-400 font-medium hover:underline">Browse all &rarr;</a>
      </div>
    </div>
  </main>

  <!-- Newsletter section -->
  <section id="newsletter" class="py-16 bg-slate-100 dark:bg-zinc-900/30 border-t border-slate-200 dark:border-zinc-800/60">
    <div class="max-w-xl mx-auto px-6 text-center">
      <h2 class="font-serif text-3xl text-slate-900 dark:text-zinc-100 mb-3">Research Updates</h2>
      <p class="text-slate-600 dark:text-zinc-400 mb-6">New studies, mechanism breakdowns, and dosing insights — delivered when they matter. No spam. Unsubscribe anytime.</p>
      <form class="flex flex-col sm:flex-row gap-3 justify-center" onsubmit="return false;">
        <input type="email" placeholder="your@email.com" class="px-4 py-3 rounded-lg border border-slate-300 dark:border-zinc-700 bg-white dark:bg-zinc-800 text-slate-900 dark:text-zinc-100 focus:outline-none focus:ring-2 focus:ring-sky-500 w-full sm:w-72">
        <button type="submit" class="px-6 py-3 bg-sky-600 hover:bg-sky-500 text-white font-semibold rounded-lg transition-colors cta-glow">Subscribe</button>
      </form>
      <p class="text-xs text-slate-500 dark:text-zinc-600 mt-3">100% evidence-based. Every claim cited.</p>
    </div>
  </section>


  <footer class="py-16 border-t border-slate-200 dark:border-zinc-900">
    <div class="max-w-7xl mx-auto px-6">
      <div class="grid grid-cols-2 md:grid-cols-6 gap-8 mb-12">
        <div class="col-span-2 md:col-span-2">
          <div class="flex items-center gap-3 mb-3">
            <div class="w-8 h-8 rounded bg-slate-100 dark:bg-zinc-800 border border-slate-200 dark:border-zinc-700 flex items-center justify-center">
              <svg class="w-4 h-4 text-sky-600 dark:text-sky-400" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"></path></svg>
            </div>
            <span class="text-slate-700 dark:text-zinc-300 font-medium">Creatine Research</span>
          </div>
          <p class="text-sm text-slate-600 dark:text-zinc-500 mb-6 max-w-xs">Evidence-based creatine research. Every claim cited. No marketing hype.</p>
          <a href="#newsletter" class="inline-block px-5 py-2 text-sm font-semibold bg-sky-600 hover:bg-sky-500 text-white rounded-md transition-colors">Research Updates</a>
        </div>
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-4">Research</p>
          <ul class="space-y-2 text-sm">
            <li><a href="/science" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Science</a></li>
            <li><a href="/dosing" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Dosing</a></li>
            <li><a href="/safety" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Safety</a></li>
          </ul>
        </div>
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-4">Applications</p>
          <ul class="space-y-2 text-sm">
            <li><a href="/sports" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">By Sport</a></li>
            <li><a href="/comparisons" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Comparisons</a></li>
            <li><a href="/quality" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Product Quality</a></li>
          </ul>
        </div>
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-4">Guides</p>
          <ul class="space-y-2 text-sm">
            <li><a href="/science/creatine-mechanisms-summary" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Science Guide</a></li>
            <li><a href="/dosing/creatine-dosing-protocols-summary" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Dosing Guide</a></li>
            <li><a href="/safety/creatine-safety-complete-guide" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Safety Guide</a></li>
            <li><a href="/quality/creatine-buying-guide" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Buying Guide</a></li>
          </ul>
        </div>
        <div>
          <p class="text-xs text-slate-500 dark:text-zinc-600 uppercase tracking-wider mb-4">Site</p>
          <ul class="space-y-2 text-sm">
            <li><a href="/" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Home</a></li>
            <li><a href="/articles" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">All Articles</a></li>
            <li><a href="https://scalewithsearch.com" target="_blank" class="text-slate-600 dark:text-zinc-500 hover:text-slate-900 dark:hover:text-white transition-colors">Scale With Search</a></li>
          </ul>
        </div>
      </div>
      <div class="pt-8 border-t border-slate-200 dark:border-zinc-900 flex flex-col md:flex-row items-center justify-between gap-4">
        <p class="text-xs text-slate-500 dark:text-zinc-700">&copy; 2026 Creatine Research. All cited sources are property of their respective authors.</p>
        <p class="text-xs text-slate-500 dark:text-zinc-700">Powered by <a href="https://scalewithsearch.com" target="_blank" class="text-slate-600 dark:text-zinc-500 hover:text-sky-500">Scale With Search</a></p>
      </div>
    </div>
  </footer>


  <script>
    // Theme
    if (localStorage.theme === 'light') {
      document.documentElement.classList.remove('dark');
    } else if (localStorage.theme === 'dark' || !('theme' in localStorage)) {
      document.documentElement.classList.add('dark');
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
      document.documentElement.classList.add('dark');
    }

    // Mega menu
    (function() {
      const triggers = document.querySelectorAll('.mega-trigger');
      const panels = document.querySelectorAll('.mega-panel');
      let activePanel = null;
      let closeTimeout = null;

      function openPanel(id) {
        clearTimeout(closeTimeout);
        panels.forEach(p => { p.classList.add('hidden'); });
        triggers.forEach(t => t.setAttribute('aria-expanded', 'false'));
        const panel = document.getElementById('mega-' + id);
        const trigger = document.querySelector('[data-mega="' + id + '"] .mega-trigger');
        if (panel) { panel.classList.remove('hidden'); activePanel = panel; }
        if (trigger) trigger.setAttribute('aria-expanded', 'true');
      }

      function scheduleClose() {
        closeTimeout = setTimeout(() => {
          panels.forEach(p => p.classList.add('hidden'));
          triggers.forEach(t => t.setAttribute('aria-expanded', 'false'));
          activePanel = null;
        }, 200);
      }

      function cancelClose() { clearTimeout(closeTimeout); }

      triggers.forEach(btn => {
        const wrapper = btn.closest('[data-mega]');
        const id = wrapper.getAttribute('data-mega');
        btn.addEventListener('mouseenter', () => openPanel(id));
        btn.addEventListener('click', (e) => {
          e.preventDefault();
          const panel = document.getElementById('mega-' + id);
          if (panel && !panel.classList.contains('hidden')) {
            panel.classList.add('hidden');
            btn.setAttribute('aria-expanded', 'false');
          } else {
            openPanel(id);
          }
        });
        wrapper.addEventListener('mouseleave', scheduleClose);
      });

      panels.forEach(panel => {
        panel.addEventListener('mouseenter', cancelClose);
        panel.addEventListener('mouseleave', scheduleClose);
      });

      document.addEventListener('click', (e) => {
        if (!e.target.closest('[data-mega]') && !e.target.closest('.mega-panel')) {
          panels.forEach(p => p.classList.add('hidden'));
          triggers.forEach(t => t.setAttribute('aria-expanded', 'false'));
        }
      });

      document.addEventListener('keydown', (e) => {
        if (e.key === 'Escape') {
          panels.forEach(p => p.classList.add('hidden'));
          triggers.forEach(t => t.setAttribute('aria-expanded', 'false'));
        }
      });
    })();

    // Mobile menu
    const mobileMenuBtn = document.getElementById('mobile-menu-btn');
    const mobileMenu = document.getElementById('mobile-menu');
    const menuIcon = document.getElementById('menu-icon');
    const closeIcon = document.getElementById('close-icon');
    if (mobileMenuBtn) {
      mobileMenuBtn.addEventListener('click', () => {
        mobileMenu.classList.toggle('hidden');
        menuIcon.classList.toggle('hidden');
        closeIcon.classList.toggle('hidden');
      });
    }

    // Mobile accordion sections
    document.querySelectorAll('.mobile-section-toggle').forEach(btn => {
      btn.addEventListener('click', () => {
        const section = btn.nextElementSibling;
        const chevron = btn.querySelector('svg');
        section.classList.toggle('hidden');
        chevron.style.transform = section.classList.contains('hidden') ? '' : 'rotate(180deg)';
      });
    });
  </script>
</body>
</html>